All Releases
 |
Myrexis to Hold Conference Call to Discuss Second Fiscal Quarter 2012 Financial Results
Feb 3, 2012
|
8.9 KB |
|
| |
SALT LAKE CITY, Feb. 3, 2012 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule compounds with novel chemical structures and distinct mechanisms of action, today announced it will hold a conference call on Thursday, February 9, 2012 at 4:30 p.m. ET (1:30 p.m. PT) to discuss financia...
|
|
Myrexis Announces Corporate Reorganization to Focus on Development Objectives
Nov 18, 2011
|
11.2 KB |
|
| |
Internal Resources Realigned to Support Development StrategyFurther 20% Reduction in Workforce and $1.8 Million in Annual Cost Reduction
SALT LAKE CITY, Nov. 18, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mech...
|
|
Myrexis Presents at 2011 EORTC/NCI/AACR Molecular Targets and Cancer Therapeutics Symposium
Nov 14, 2011
|
14.4 KB |
|
| |
SALT LAKE CITY, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action, today announced that it presented two posters at the 2011 European Organization for Research and Treatment of Cancer (EORTC...
|
|
Myrexis Reports First Quarter Fiscal Year 2012 Results
Nov 9, 2011
|
17.3 KB |
|
| |
SALT LAKE CITY, Nov. 9, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action, today reported financial results for its fiscal first quarter ended September 30, 2011.
Robert J. Lollini, President and...
|
|
CORRECTION -- Myrexis to Hold Conference Call to Discuss First Quarter 2012 Financial Results
Nov 3, 2011
|
6.3 KB |
|
| |
SALT LAKE CITY, Nov. 3, 2011 (GLOBE NEWSWIRE) -- In a press release issued earlier today by Myrexis, Inc. (Nasdaq:MYRX) with the same headline, please note that the conference call will be held on Wednesday, November 9, 2011. All other information remains accurate.CONTACT: Myrexis, Inc.
Wayne Laslie
Chief Operating Officer
...
|
|
Myrexis to Present at 2011 EORTC/NCI/AACR Molecular Targets and Cancer Therapeutics Symposium
Nov 3, 2011
|
10.0 KB |
|
| |
SALT LAKE CITY, Nov. 3, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action, today announced it will present two posters at the 2011 European Organization for Research and Treatment of Cancer (EORTC), ...
|
|
Myrexis to Hold Conference Call to Discuss First Quarter 2012 Financial Results
Nov 3, 2011
|
9.6 KB |
|
| |
SALT LAKE CITY, Nov. 3, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action, today announced it will hold a conference call on Thursday, November 9, 2011 at 4:30 p.m. ET (1:30 p.m. PT) to discuss finan...
|
|
Myrexis Appoints Jason M. Aryeh to its Board of Directors
Oct 20, 2011
|
9.8 KB |
|
| |
SALT LAKE CITY, Oct. 20, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action, today announced the appointment of Jason M. Aryeh, Founder and General Partner of JALAA Equities L.P., to its Board of Dire...
|
|
Myrexis to Participate in the 2011 UBS Global Life Sciences Conference
Sep 14, 2011
|
9.5 KB |
|
| |
SALT LAKE CITY, Sept. 14, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule compounds with novel chemical structures and distinct mechanisms of action, today announced that Robert Lollini, President and Chief Executive Officer, will be presenting at the 2011 UBS Global Life Sc...
|
|
Myrexis to Present at 2011 Rodman and Renshaw Healthcare Conference
Sep 9, 2011
|
9.9 KB |
|
| |
SALT LAKE CITY, Sept. 9, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule compounds with novel chemical structures and distinct mechanisms of action, today announced that Robert Lollini, President and Chief Executive Officer, will be presenting at the 2011 Rodman and Renshaw ...
|
|
Myrexis Reports Fourth Quarter and Fiscal Year 2011 Results
Sep 8, 2011
|
21.7 KB |
|
| |
Clinical Development Strategy UpdateConference Call Today at 4:30 pm EDT
SALT LAKE CITY, Sept. 8, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule compounds with novel chemical structures and distinct mechanisms of action, today reported financial results for its fiscal f...
|
|
Myrexis Board of Directors Appoints Robert Lollini CEO
Sep 8, 2011
|
10.1 KB |
|
| |
SALT LAKE CITY, Sept. 8, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc., (Nasdaq:MYRX) today announced that its Board of Directors has appointed current interim President and Chief Executive Officer (CEO) and Chief Financial Officer (CFO) Robert Lollini as its CEO, effective immediately. Mr. Lollini was also appointed as a member of the Board.
The Boar...
|
|
Myrexis to Hold Conference Call to Discuss Fiscal Year 2011 Results and Program Updates
Sep 2, 2011
|
9.5 KB |
|
| |
SALT LAKE CITY, Sept. 2, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule compounds with novel chemical structures and distinct mechanisms of action, today announced it will hold a conference call on Thursday, September 8, 2011 at 4:30 p.m. ET (1:30 p.m. PT) to discuss financ...
|
|
Myrexis Announces Executive Management Changes
Jul 22, 2011
|
11.4 KB |
|
| |
SALT LAKE CITY, July 22, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced that Adrian N. Hobden, Ph.D. has resigned as President, Chief Executive Officer and a member of the Board of Directors, effective July 21, 2011. The Board of Di...
|
|
Myrexis to Participate in Stifel Nicolaus 2011 Orphan Drug One-on-One Conference
Jun 30, 2011
|
12.5 KB |
|
| |
SALT LAKE CITY, June 30, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced that Adrian Hobden, Ph.D., President and Chief Executive Officer, and Robert Lollini, Chief Financial Officer and Treasurer, will participate in one-on-one meet...
|
|
Myrexis Reports Azixa(R) Phase 2 Study Results at 2011 American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 6, 2011
|
18.0 KB |
|
| |
Azixa is Active and Well Tolerated in Patients Who Failed First-Line TherapyMulti-Dose Efficacy Presented From Cancer Metabolism Inhibitor Program
SALT LAKE CITY, June 6, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced presentati...
|
|
Myrexis Presents Oral Anti-Interferon Preclinical Data at EULAR Annual European Congress of Rheumatology
May 26, 2011
|
13.8 KB |
|
| |
SALT LAKE CITY, May 26, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today presented encouraging preclinical findings for its oral anti-interferon (OAI) candidate, MPI-0485520, at the European League Against Rheumatism (EULAR) Annual European Con...
|
|
Myrexis to Present at Jefferies 2011 Global Healthcare Conference
May 25, 2011
|
13.2 KB |
|
| |
SALT LAKE CITY, May 25, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced that Adrian Hobden, Ph.D., President and Chief Executive Officer, is scheduled to present an overview of the Company at the Jefferies and Company 2011 Global Hea...
|
|
Myrexis to Report Azixa® Phase 2 Study Results at 2011 American Society of Clinical Oncology (ASCO) Annual Meeting
May 18, 2011
|
15.3 KB |
|
| |
SALT LAKE CITY, May 18, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced it will report Phase 2 clinical study results from its lead product candidate Azixa® at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting...
|
|
Myrexis Reports Third Quarter Fiscal 2011 Results
May 10, 2011
|
23.4 KB |
|
| |
Upcoming Events
Report Azixa® Phase 2a monotherapy results in recurrent glioblastoma multiforme (GBM) patients naive to treatment with Avastin® (bevacizumab) at American Society for Clinical Oncology (ASCO)
Report Phase 1 study results for MPC-3100 (fully-synthetic Hsp90 inhibitor) in solid and hematological refractory cancer p...
|
|
|
